Equity Research

May 10, 2021 BSE Sensex: 49502

ICICI Securities Limited is the author and distributor of this report

Q4FY21 result review and TP change

Specialty Chemicals

Target price: Rs3,073 Earnings revision

(%)	FY22E	FY23E
Sales	↑ 2.9	↑ 3.5
EBITDA	↑ 1.9	↑ 2.9
EPS	↓ 1.2	↓ 1.4


Target price revision Rs3,073 from Rs2,338

Shareholding pattern

	9		
	Sep '20	Dec '20	Mar 21
Promoters Institutional	30.5	30.5	30.2
investors	38.4	41.4	40.9
MFs and other Insurance Cos.	17.0 0.1	13.9 0.0	13.4 0.0
FIIs	24.3	27.5	27.5
Others	28.1	28.1	28.9

Source: NSF

Price chart



Research Analyst:

Saniesh Jain sanjesh.jain@icicisecurities.com +91 22 6637 7153

Navin Fluorine International

REDUCE Maintained Rs3.223

Demanding valuation caps upside

Navin Fluorine International's (NFIL) Q4FY21 EBITDA grew 23% YoY on low base and steady performance in CRAMS and specialty chemicals. It expects specialty chemicals revenue growth in mid-teens for FY22. CRAMS will continue to grow albeit at a lower magnitude; it is sitting on projects for 25 molecules in phase 1 & 2. Gross profit margins have been range bound despite significant improvement in contribution from high value business, which is key to watch. HPP and MPP plants could be delayed by one-quarter on second wave of covid. Company remains excited on new opportunities and plans for a new innovation centre outside India. We have cut EPS on deconsolidation of CCVL, but raise valuation multiple to 40x (from 30x) on rising opportunities and target price to Rs3,073 (from Rs2,338). Maintain REDUCE.

- Low base drives revenue growth. Standalone revenue rose 22.3% YoY to Rs3.2bn driven by CRAMS revenue rise of 39% to Rs0.75bn, and specialty chemicals revenue growth of 26% to Rs1.3bn. Ref-gas and inorganic revenues rose 3.6% / 15.7% YoY to Rs580mn and Rs590mn, respectively. Specialty chemicals revenue to grow in mid-teens. which will be driven by agro-chemicals in FY22 and CRAMS will continue to grow. It has 25 molecules in initial stages of product development in CRAMS, which have come from the existing customers (repeat business) and provide good visibility for revenue growth.
- Gross margin hurt from inferior mix. Gross margin dipped 150bps YoY to 52.7% and was impacted from 1) lower sales of R-22 in domestic market and non-emissive use, which have higher realisations; and 2) few high margin product sales in specialty chemicals was lower due to logistical issues. EBITDA rose 25% YoY to Rs842mn and EBITDA margin came in at 26% (up 60bps YoY). Consolidated revenue / EBITDA and PBT grew 21.6% / 22.5% and 51% YoY. It had tax reversal in Q4FY20 and exceptional gains in Q4FY21 and therefore, net profit is not comparable.
- Steady revenue growth outlook for FY22. NFIL has guided for a mid-teens growth in ► specialty chemicals for FY22 largely driven by debottlenecking of few capacities; new MPP plant should help growth only from FY23. CRAMS should see continued growth; magnitude of growth may be small, but it remains confident of sustained growth over the years as it continues to build on capabilities and relationships. NFIL is planning for an innovation centre outside India for new product development and applications.
- Other highlights. 1) Impact from rise in input cost is minimum and limited to solvents, margin compression is on inferior sale mix; 2) quality of business improving from being second to fourth supplier; it is working on molecule where either it is a primary supplier; or second supplier with first in eastern market; 3) NFIL is not excited on import substitution market as pricing needs to be matched to Chinese supplier, but it is focused in innovative products for exports market. Export agrochemicals intermediate market looks strong; and 4) it has been working on partnerships with chemical companies to have deeper understanding. It is seeking board approval for small capex in new product.

Market Cap	Rs159bn/US\$2.2bn	Year to Mar	FY20	FY21P	FY22E	FY23E
Reuters/Bloomberg	NAFL.BO/NFIL IN	Revenue (Rs bn)	10.6	11.8	14.1	20.4
Shares Outstanding (mn)	49.5	Net Income (Rs bn)	4.1	2.4	3.0	3.8
52-week Range (Rs)	3620/1410	Recurring EPS (Rs)	82.6	52.0	60.4	76.8
Free Float (%)	69.8	% Chg YoY	173.9	(37.0)	16.1	27.2
FII (%)	27.5	P/E (x)	39.0	61.9	53.3	42.0
Daily Volume (US\$/'000)	8,641	CEPS (Rs)	90.1	61.0	68.5	94.0
Absolute Return 3m (%)	26.1	EV/E (x)	58.9	49.7	39.8	28.8
Absolute Return 12m (%)	124.7	Dividend Yield (%)	0.3	0.3	0.6	0.7
Sensex Return 3m (%)	(3.4)	RoCE (%)	28.3	11.8	15.2	16.8
Sensex Return 12m (%)	58.2	RoE (%)	32.9	17.0	17.4	19.4

Please refer to important disclosures at the end of this report

INDIA

FICICISecurities

Table 1: NFIL (consolidated financials)

Rs mn	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21	QoQ (%)	YoY (%)
Net revenue	2,766	2,149	3,189	3,091	3,364	8.8	21.6
Cost of Goods sold	1,257	910	1,432	1,425	1,607	12.7	27.8
Gross profit	1,509	1,240	1,757	1,666	1,758	5.5	16.5
Gross profit margin (%)	54.6	57.7	55.1	53.9	52.2		
Employee cost	351	346	340	362	369	2.1	5.1
% of revenue	12.7	16.1	10.7	11.7	11.0		
Other expenses	470	355	510	499	546	9.4	16.2
% of revenue	17.0	16.5	16.0	16.1	16.2		
Total expenses	821	701	850	861	915	6.3	11.5
EBITDA	688	538	907	805	842	4.7	22.5
EBITDA margin (%)	24.9	25.0	28.4	26.0	25.0		
Depreciation	111	107	109	110	116	5.2	4.5
EBIT	577	431	799	695	727	4.6	26.0
EBIT margin (%)	20.9	20.1	25.0	22.5	21.6		
Other income	57	362	97	99	233	135.1	309.7
Finance cost	5	3	4	4	8	111.3	55.4
PBT	629	790	891	790	952	20.5	51.4
Tax expenses	(2,072)	260	247	226	375	66.1	(118.1)
ETR (%)	(329.5)	32.9	27.7	28.6	39.4		. ,
Exceptional item	. ,				155		
Profit from JV	26	31	34	24	16		
PAT	2,727	560	678	589	748	27.0	(72.6)
Net profit margin (%)	98.6	26.1	21.3	19.1	22.2		
Recurring EPS (Rs)	55.1	11.3	13.7	11.9	12.0	0.7	(78.3)

Source: Company data, I-Sec research

Table 2: NFIL (standalone financials)

Rs mn	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21	QoQ (%)	YoY (%)
Net revenue	2,650	2,047	3,077	2,966	3,240	9.2	22.3
Cost of Goods sold	1,209	852	1,367	1,359	1,532	12.8	26.8
Gross profit	1,441	1,196	1,710	1,607	1,708	6.3	18.5
Gross profit margin (%)	54.4	58.4	55.6	54.2	52.7		
Employee cost	300	291	283	294	325	10.6	8.4
% of revenue	11.3	14.2	9.2	9.9	10.0		
Other expenses	470	384	492	490	541	10.3	15.2
% of revenue	17.7	18.8	16.0	16.5	16.7		
Total expenses	769	675	775	784	866	10.4	12.5
EBITDA	672	521	935	823	842	2.3	25.3
EBITDA margin (%)	25.4	25.4	30.4	27.8	26.0		
Depreciation	102	99	100	101	106	5.1	3.9
EBIT	570	422	835	722	736	1.9	29.2
EBIT margin (%)	21.5	20.6	27.1	24.3	22.7		
Other income	53	356	88	91	197	116.4	273.3
Finance cost	5	2	3	3	6	109.8	23.3
PBT	618	776	920	810	927	14.4	50.1
Exceptional item	-	-	-	-	662		
Tax expenses	(2,069)	260	246	223	373	67.0	(118.0)
ETR (%)	(335.1)	33.5	26.8	27.6	40.2		· · ·
PAT	2,687	516	673	587	1,216	107.3	(54.7)
Net profit margin (%)	101.4	25.2	21.9	19.8	37.5		
Recurring EPS (Rs)	54.5	10.4	13.6	11.9	11.2	(5.6)	(79.4)

Source: Company data, I-Sec research

Table 3: NFIL – segmental revenues

Rs mn	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21	QoQ (%)	YoY (%)
Refrigerants	560	460	580	470	580	23.4	3.6
Inorganic Fluorides	510	280	490	570	590	3.5	15.7
Specialty Chemicals	1,040	970	1,020	1,220	1,310	7.4	26.0
CRAMS	540	340	990	710	750	5.6	38.9
Total revenue	2,650	2,050	3,080	2,970	3,230	8.8	21.9
Contribution (%)							
Refrigerants	21.1	22.4	18.8	15.8	18.0		
Inorganic Fluorides	19.2	13.7	15.9	19.2	18.3		
Specialty Chemicals	39.2	47.3	33.1	41.1	40.6		
CRAMS	20.4	16.6	32.1	23.9	23.2		


Source: Company data, I-Sec research

Table 4: NFIL – geographic revenues

Rs mn	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21	QoQ (%)	YoY (%)
Domestic							
Refrigerants	314	271	275	249	328	31.8	4.7
Inorganic Fluorides	449	244	188	359	367	2.2	(18.1)
Specialty Chemicals	603	446	668	785	818	4.2	35.6
CRAMS	-	-	-	-	-		
Total Domestic	1,366	961	1,130	1,394	1,514	8.6	10.9
Exports							
Refrigerants	246	189	306	221	252	14.0	2.2
Inorganic Fluorides	61	36	302	211	223	5.7	263.7
Specialty Chemicals	437	524	352	445	492	10.6	12.6
CRAMS	540	340	990	710	750	5.6	38.9
Total Exports	1,284	1,089	1,950	1,586	1,716	8.2	33.6


Source: Company data, I-Sec research

Chart 1: Export realisation for R-22



Source: I-Sec research, Gol

Chart 2: Fluorspar (key raw material) prices



Source: I-Sec research, Gol

Table 5: Earnings revision

	Revised		Earlie	r	% change		
(Rs mn)	FY22E	FY23E	FY22E	FY23E	FY22E	FY23E	
Revenue	14,102	20,412	13,707	19,721	2.9	3.5	
EBITDA	3,951	5,537	3,878	5,380	1.9	2.9	
EBITDA margin (%)	28.0	27.1	28.3	27.3			
PAT	2,989	3,801	3,025	3,856	(1.2)	(1.4)	
EPS (Rs)	60	77	61	78	(1.2)	(1.4)	

Source: I-Sec research

Financial summary

Table 6: Profit & loss statement

(Rs mn, year ending March 31	1)			
	FY20	FY21P	FY22E	FY23E
Operating Income (Sales)	10,616	11,794	14,102	20,412
Operating Expenses	7,981	8,701	10,151	14,875
EBITDA	2,635	3,093	3,951	5,537
% margins	24.8	26.2	28.0	27.1
Depreciation & Amortisation	370	442	400	847
Net Interest	20	18	10	10
Other Income	333	790	480	433
Recurring PBT	2,578	3,423	4,022	5,112
Add: Extraordinaries	-	155	-	-
Less: Taxes	(1,436)	1,108	1,032	1,311
- Current tax	(1,436)	1,108	1,032	1,311
- Deferred tax				
Add: Share of JV	72	105	-	-
Net Income (Reported)	4,086	2,575	2,989	3,801
Recurring Net Income	4,086	2,420	2,989	3,801

Source: Company data, I-Sec research

Table 7: Balance sheet

, year ending March 3	1)
-----------------------	----

	FY20	FY21P	FY22E	FY23E
Assets				
Total Current Assets of which cash & cash	8,504	10,399	8,136	11,295
<i>eqv.</i> Total Current Liabilities &	2,837	4,391	905	666
Provisions	2,149	2,418	2,900	4,105
Net Current Assets	6,354	7,980	5,236	7,190
Investments	2,504	2,504	2,504	2,504
of which				
Strategic/Group	955	955	955	955
Other Marketable	1,549	1,549	1,549	1,549
Net Fixed Assets	4,248	4,853	9,678	12,371
Goodwill	878	878	878	878
Total Assets	13,984	16,217	18,297	22,943
Liabilities				
Borrowings	14	214	214	2,214
Deferred tax liability	(151)	(151)	(151)	(151)
Minority Interest	-	-	-	-
Equity Share Capital	99	99	99	99
Face Value per share				
(Rs)	2.0	2.0	2.0	2.0
Reserves & Surplus	14,023	16,055	18,136	20,782
Net Worth	14,122	16,154	18,234	20,881
Total Liabilities	13,984	16,217	18,297	22,943

Source: Company data, I-Sec research

Table 8: Quarterly trend

(Rs mn,	year	ending I	March 3	31)	

	Jun-20	Sep-20	Dec-20	Mar-21
Net sales	2,149	3,189	3,091	3,364
% growth (YoY)	(14.5)	16.8	18.7	21.6
EBITDA	538	935	823	842
Margin (%)	25.0	29.3	26.6	25.0
Other income	362	88	91	197
Add: Extra ordinaries	-	-	-	662
Net profit	560	673	587	1,216
0				

Source: Company data

Table 9: Cashflow statement

(Rs mn,	year ending March 31)	
---------	-----------------------	--

FY20	FY21P	FY22E	FY23E
2,272	2,245	2,919	4,226
(706)	(73)	(740)	(2,194)
(1,077)	(1,047)	(5,225)	(3,540)
489	1,125	(3,046)	(1,508)
1,929	790	480	433
12	-	-	-
(27)	200	-	2,000
(794)	(562)	(919)	(1,165)
. ,	. ,	. ,	. ,
1,609	1,553	(3,485)	(240)
	2,272 (706) (1,077) 489 1,929 12 (27) (794)	2,272 2,245 (706) (73) (1,077) (1,047) 489 1,125 1,929 790 12 - (27) 200 (794) (562)	2,272 2,245 2,919 (706) (73) (740) (1,077) (1,047) (5,225) 489 1,125 (3,046) 1,929 790 480 12 - - (27) 200 - (794) (562) (919)

Source: Company data, I-Sec research

Table 10: Key ratios

(Year ending March 31)

(Year ending March 31)				
	FY20	FY21P	FY22E	FY23E
Per Share Data (in Rs.)				
Recurring EPS	82.6	52.0	60.4	76.8
Reported EPS	82.6	52.0	60.4	76.8
Recurring Cash EPS	90.1	61.0	68.5	94.0
Dividend per share (DPS)	11.0	11.0	18.4	23.4
Book Value per share (BV)	285.4	326.5	368.5	422.0
Growth Ratios (%)				
Operating Income	6.6	11.1	19.6	44.7
EBITDA	20.7	17.4	27.8	44.7
Recurring Net Income	174.0	(37.0)	16.1	27.2
Diluted Recurring EPS	174.0	(37.0)	16.1	27.2
Diluted Recurring CEPS	152.2	(37.0)	12.3	37.2
Diluted Recurring CEFS	192.2	(32.3)	12.5	57.2
Valuation Ratios (% YoY)				
P/E	39.0	61.9	53.3	42.0
P/CEPS	35.8	52.9	47.1	34.3
P/BV	11.3	9.9	8.7	7.6
EV / EBITDA	58.9	49.7	39.8	28.8
EV / Operating Income	14.6	13.0	11.1	7.8
EV / Operating FCF	264.0	136.7	(51.6)	(105.8)
	204.0	150.7	(31.0)	(105.0)
Operating Ratios				
Other Income / PBT (%)	12.9	23.1	11.9	8.5
Effective Tax Rate (%)	(55.7)	32.4	25.7	25.6
NWC / Total Assets (%)	(33.7) 24.9	21.9	23.7	28.2
Inventory Turnover (days)	24.9 54.3	50.3	23.3 49.7	49.5
Receivables (days)	75.1	70.2	71.3	73.2
Payables (days)	33.7	34.6	35.5	35.4
Net Debt/EBITDA Ratio (x)	(1.7)	(1.9)	(0.6)	(0.0)
Capex % of sales	10.1	(1.9)	(0.0) 37.0	(0.0)
Caper / Or sales	10.1	0.5	57.0	17.5
Profitability Ratios (%)				
Recur. Net Income Margins	38.5	21.8	21.2	18.6
RoCE	28.3	11.8	15.2	16.8
RolC	43.5	17.8	20.0	18.9
RoNW	32.9	17.0	17.4	19.4
Dividend Yield	0.3	0.3	0.6	0.7
Gross Margins	54.4	54.4	55.1	53.8
EBITDA Margins	24.8	26.2	28.0	27.1
Source: Company data See r	2 1.0			

Source: Company data, I-Sec research

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise) BUY: >15 return; ADD: 5 to 15 return; HOLD: Negative 5 to Positive 5 return; REDUCE: Negative 5 to Negative 15 return; SELL: < negative 15 return

ANALYST CERTIFICATION

I/We, Sanjesh Jain, PGDM; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis cevtre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICIĆI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report. We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.